August 2022

The long-term consequences of untreated—and prevalent—sleep disorders in children and adolescents point to a need for a focus on this field of care.

Following positive phase 3 findings, a second study featuring more than 300 patients will aim to confirm PXT3003’s effect in patients with Charcot-Marie-Tooth disease type 1a.

Joseph E. Sullivan, MD; Kelly Knupp, MD; Mary Anne Meskis; and Tracy Dixon-Salazar, PhD, share insight into the patient and provider journey of LGS and Dravet syndrome, from diagnosis through treatment.

Identified implications of the endocannabinoid system in migraine physiology suggest that this pathway might hold therapeutic potential for some headache disorders.

Neuromuscular medicine has entered an era of genetic therapy, opening the doors to questions about possible combination approaches and earlier initiation of treatment.

Despite the availability of medications to relieve OFF episodes in Parkinson disease, widespread adoption of on-demand therapies has been less-than-ideal, marking the need to shift the treatment paradigm in PD.

In addition to filing under the accelerated approval pathway, Eisai will submit for a traditional approval of lecenamab before the end of the first quarter of 2023, seeking an indication for mild cognitive impairment because of Alzheimer disease.

In the original panel discussion, held in March 2022, the majority of members of the committee voted that AMX0035 did not fully demonstrate sufficient efficacy as a treatment for ALS.

In the comparator study between ponesimod and teriflunomide, the risk of both 12- and 24-week confirmed disability accumulation at week 108 was significantly different between MAGNIMS score groups.

Investigators utilized a social media listening tool to evaluate and scale mentions of disease-modifying therapy use by women with multiple sclerosis, with the majority of concerns focused on safety and treatment reinitiation in the postpartum period.

Both ozanimod doses were associated with greater median reductions in plasma neurofilament light and mean improvements in SDMT score change than interferon beta-1a at month 12 of treatment.